Insider Activity Spotlight: Tactile Systems Technology Inc.

A Dual‑Side View of the CFO’s Recent Dealings On February 20, 2026, Chief Financial Officer Elaine M. Birkemeyer executed a significant purchase of 15,575 shares, adding to her holdings that now total 148,038 shares. The transaction was priced at $0, indicating that the shares were acquired through the vesting of performance‑based stock units (PSUs). The same day she also bought an additional 6,765 shares and, earlier that month, a larger block of 3,579 shares—each vesting in the same performance period. The pattern shows a clear, consistent use of performance‑based equity to align her interests with shareholders and the long‑term success of Tactile.

Two days later, Birkemeyer sold 5,322 shares and 196 shares at an average of $28.28 and $28.69 respectively. These sales were explicitly tied to covering taxes on the settlement of her PSUs. The timing and price of the sales suggest a routine tax‑planning maneuver rather than an attempt to signal downside sentiment. Investors can interpret these transactions as a CFO who is comfortable with the company’s performance trajectory and is using equity compensation to demonstrate commitment.

Implications for Investors and the Company’s Outlook The CFO’s active buying of vested equity aligns her financial fate with the stock price, reinforcing confidence that management is investing in the company’s future. The simultaneous tax‑cover sales are routine and do not indicate an impending liquidation or liquidity crunch. The fact that the CFO’s holdings have steadily increased over the past year—adding 23,008 shares on February 19, 2026—further underscores her confidence in Tactile’s growth prospects, particularly in the high‑margin niche of lymphedema and chronic swelling devices.

From a market perspective, the stock’s recent 5.9 % rise on earnings day and a 97.31 % year‑to‑date gain suggest robust investor enthusiasm. The CFO’s transactions, coupled with the broader insider activity from CEO Sheri Dodd and Senior VP Kristie Burns, reinforce the narrative of a management team that is actively engaged in the company’s upside. For investors, this may translate into a more bullish stance, especially as Tactile continues to expand its product pipeline and secure regulatory approvals.

Birkemeyer Elaine M.: A Profile of a Commitment‑Driven CFO Historically, Birkemeyer’s transactions have been dominated by performance‑based vesting rather than market‑price purchases. Her first recorded transaction in the data set was a 23,008‑share purchase on February 19, 2026—priced at zero—followed by a series of 3,579, 6,765, and 15,575 share acquisitions, all tied to PSUs vesting in 2026. The pattern indicates a disciplined approach: she accumulates equity in lock‑step with measurable company milestones rather than speculative market movements. Moreover, her decision to sell shares to cover taxes rather than liquidate for cash signals a long‑term horizon and an avoidance of market‑timing pitfalls.

This history suggests that Birkemeyer is not merely a passive shareholder; she is actively leveraging performance incentives to align her success with the company’s earnings. The CFO’s consistent buying activity, coupled with the company’s strong financial fundamentals—a P/E of 34.26 and a market cap of roughly $634 million—points to a management team that trusts in Tactile’s product pipeline and market expansion.

Conclusion The CFO’s latest insider transactions—both purchases and tax‑cover sales—are emblematic of a management team that is confident in Tactile’s trajectory and committed to aligning its interests with shareholders. Investors should view these moves as reinforcing signals rather than red flags, especially when considered alongside the company’s strong earnings performance and bullish market sentiment. The CFO’s disciplined approach to equity compensation, combined with the broader insider activity, paints a picture of a leadership group that believes in the long‑term value creation potential of Tactile Systems Technology Inc.

DateOwnerTransaction TypeSharesPrice per ShareSecurity
2026-02-20Birkemeyer Elaine M. (CHIEF FINANCIAL OFFICER)Buy3,579.00N/ACommon Stock
2026-02-20Birkemeyer Elaine M. (CHIEF FINANCIAL OFFICER)Buy6,765.00N/ACommon Stock
2026-02-20Birkemeyer Elaine M. (CHIEF FINANCIAL OFFICER)Buy15,575.00N/ACommon Stock
2026-02-23Birkemeyer Elaine M. (CHIEF FINANCIAL OFFICER)Sell5,322.0028.28Common Stock
2026-02-23Birkemeyer Elaine M. (CHIEF FINANCIAL OFFICER)Sell196.0028.69Common Stock
2026-02-20Dodd Sheri Louise (Chief Executive Officer)Buy19,751.00N/ACommon Stock
2026-02-20Dodd Sheri Louise (Chief Executive Officer)Buy28,216.00N/ACommon Stock
2026-02-23Dodd Sheri Louise (Chief Executive Officer)Sell14,703.0028.28Common Stock
2026-02-23Dodd Sheri Louise (Chief Executive Officer)Sell537.0028.69Common Stock
2026-02-20Burns Kristie (Sr. VP Mktg & Clinical Affairs)Buy3,490.00N/ACommon Stock
2026-02-20Burns Kristie (Sr. VP Mktg & Clinical Affairs)Buy4,058.00N/ACommon Stock
2026-02-20Burns Kristie (Sr. VP Mktg & Clinical Affairs)Buy7,123.00N/ACommon Stock
2026-02-23Burns Kristie (Sr. VP Mktg & Clinical Affairs)Sell4,279.0028.28Common Stock
2026-02-23Burns Kristie (Sr. VP Mktg & Clinical Affairs)Sell160.0028.69Common Stock